A Study of Zilovertamab Vedotin (MK-2140) (VLS-101) in Participants With Solid Tumors (MK-2140-002)
Status:
Recruiting
Trial end date:
2023-04-28
Target enrollment:
Participant gender:
Summary
This is a study evaluating the efficacy, safety, pharmacokinetics, immunogenicity, and
pharmacodynamics of zilovertamab vedotin in participants with metastatic solid tumors
including triple-negative breast cancer (TNBC), non-squamous non-small-cell lung cancer
(NSCLC), estrogen receptor-positive breast cancer, progesterone receptor-positive breast
cancer and human epidermal growth factor 2 positive carcinoma of breast.